APA-话题@MedSci

#APA#

153篇内容 | 3633人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1338115, encodeId=6c221338115b4, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=乌云笼罩默沙东——抗凝血剂vorapaxar再度出现出血风险, objectType=article, longId=5395, objectId=594853956a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=594853956a, replyNumber=0, likeNumber=57, createdTime=2012-04-18, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=594853956a, moduleTitle=乌云笼罩默沙东——抗凝血剂vorapaxar再度出现出血风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=594853956a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338114, encodeId=0b85133811453, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=NEJM：新型抗血小板药物Vorapaxar可降低心脏血管疾病死亡率, objectType=article, longId=4491, objectId=47a7449156, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47a7449156, replyNumber=0, likeNumber=58, createdTime=2012-04-02, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47a7449156, moduleTitle=NEJM：新型抗血小板药物Vorapaxar可降低心脏血管疾病死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47a7449156)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338113, encodeId=4154133811361, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=新版APASL《丙型肝炎病毒感染共识和治疗程序》发布, objectType=article, longId=4362, objectId=b6b6436291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6b6436291, replyNumber=0, likeNumber=0, createdTime=2012-03-24, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6b6436291, moduleTitle=新版APASL《丙型肝炎病毒感染共识和治疗程序》发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6b6436291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338112, encodeId=0237133811253, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=陈成伟：CHB初治药物选择 [APASL 2012], objectType=article, longId=4292, objectId=19864292ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19864292ab, replyNumber=0, likeNumber=0, createdTime=2012-03-12, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19864292ab, moduleTitle=陈成伟：CHB初治药物选择 [APASL 2012], moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19864292ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338111, encodeId=9f2013381112a, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=牛俊奇：从2012 新版APASL指南看替比夫定的临床应用, objectType=article, longId=4220, objectId=dbab4220d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbab4220d4, replyNumber=0, likeNumber=58, createdTime=2012-03-06, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbab4220d4, moduleTitle=牛俊奇：从2012 新版APASL指南看替比夫定的临床应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbab4220d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338110, encodeId=c2c9133811099, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=dapagliflozin联合二甲双胍能降低糖尿病患者腰围和脂肪量, objectType=article, longId=4169, objectId=82744169af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82744169af, replyNumber=0, likeNumber=84, createdTime=2012-03-05, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82744169af, moduleTitle=dapagliflozin联合二甲双胍能降低糖尿病患者腰围和脂肪量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82744169af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338109, encodeId=477e133810949, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=2012年APASL《亚太地区慢性乙型肝炎管理共识》, objectType=article, longId=4160, objectId=15e2416008, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15e2416008, replyNumber=0, likeNumber=78, createdTime=2012-02-29, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15e2416008, moduleTitle=2012年APASL《亚太地区慢性乙型肝炎管理共识》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15e2416008)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338108, encodeId=2f5513381082f, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=庄辉：2012版APASL慢性乙型肝炎诊疗指南更新要点, objectType=article, longId=4159, objectId=82184159b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82184159b7, replyNumber=0, likeNumber=76, createdTime=2012-02-29, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82184159b7, moduleTitle=庄辉：2012版APASL慢性乙型肝炎诊疗指南更新要点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82184159b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338107, encodeId=dde9133810edf, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=APASL发布《亚太地区慢性乙型肝炎治疗共识（2012更新版）》, objectType=article, longId=4137, objectId=a796413e78, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a796413e78, replyNumber=0, likeNumber=76, createdTime=2012-02-26, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a796413e78, moduleTitle=APASL发布《亚太地区慢性乙型肝炎治疗共识（2012更新版）》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a796413e78)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338106, encodeId=102b133810649, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=2012 APASL会议日程, objectType=article, longId=4073, objectId=c92340e325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c92340e325, replyNumber=0, likeNumber=72, createdTime=2012-02-19, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c92340e325, moduleTitle=2012 APASL会议日程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c92340e325)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338105, encodeId=ace2133810580, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=APASL将发乙丙肝新指南, objectType=article, longId=4071, objectId=b2f740e1a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2f740e1a7, replyNumber=0, likeNumber=75, createdTime=2012-02-19, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2f740e1a7, moduleTitle=APASL将发乙丙肝新指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2f740e1a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338104, encodeId=079913381048a, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=糖尿病新药Dapagliflozin被FDA否决, objectType=article, longId=3701, objectId=fc703e01f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc703e01f4, replyNumber=0, likeNumber=81, createdTime=2012-01-21, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc703e01f4, moduleTitle=糖尿病新药Dapagliflozin被FDA否决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc703e01f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338103, encodeId=2b3f1338103db, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=APASL慢性乙型肝炎管理指南(2008版), objectType=article, longId=2059, objectId=77a02059a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77a02059a1, replyNumber=0, likeNumber=66, createdTime=2010-08-25, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77a02059a1, moduleTitle=APASL慢性乙型肝炎管理指南(2008版), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77a02059a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

APA

2020-05-29

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

乌云笼罩默沙东——抗凝血剂vorapaxar再度出现出血风险

2012-04-18

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

NEJM：新型抗血小板药物Vorapaxar可降低心脏血管疾病死亡率

2012-04-02

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

新版APASL《丙型肝炎病毒感染共识和治疗程序》发布

2012-03-24

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

陈成伟：CHB初治药物选择 [APASL 2012]

2012-03-12

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

牛俊奇：从2012 新版APASL指南看替比夫定的临床应用

2012-03-06

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

dapagliflozin联合二甲双胍能降低糖尿病患者腰围和脂肪量

2012-03-05

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

2012年APASL《亚太地区慢性乙型肝炎管理共识》

2012-02-29

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

庄辉：2012版APASL慢性乙型肝炎诊疗指南更新要点

2012-02-29

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

APASL发布《亚太地区慢性乙型肝炎治疗共识（2012更新版）》

2012-02-26

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

2012 APASL会议日程

2012-02-19

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

APASL将发乙丙肝新指南

2012-02-19

智慧医人 (审核中...)

前往app查看评论内容

#APA#

糖尿病新药Dapagliflozin被FDA否决

2012-01-21

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

APASL慢性乙型肝炎管理指南(2008版)

2010-08-25

科室
- - 订阅+
  - 更多科室
工具
服务